Elliott M. Antman, M.D., Brigham and Women's Hospital
http://www.medpagetoday.com
ORLANDO, Nov. 4 -- Prasugrel, a super-potent investigational antiplatelet agent, significantly reduced myocardial infarction, urgent target vessel revascularization, and stent thrombosis compared with clopidogrel (Plavix), researchers reported here today.
Just approved in Europe 12/18!
ShellBeachGirl 3 years ago